Literature DB >> 10480306

Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis.

T Yoshida1, H Koga, F Saitoh, M Sakamoto, M Harada, H Yoshida, S Sakisaka, M Sata.   

Abstract

Interstitial pneumonitis (IP) is a serious complication in polymyositis/dermatomyositis (PM/DM), leading to significant morbidity or mortality. Here, we report the successful treatment by pulse intravenous administration of cyclophosphamide in the early course of lung involvement in PM, and with subsequent low-dosage oral administration of azathioprine in a patient with steroid-resistant IP associated with PM/DM. Although the precise pharmacological mechanism induced by cyclophosphamide in this disease remains unclear, such a cytotoxic drug raises the possibility of control of steroid-resistant PM/DM-associated IP when used in the early course of IP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10480306     DOI: 10.2169/internalmedicine.38.733

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

Review 1.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

Review 2.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

3.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

4.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I-Jung Chen; Yeong-Jian Jan Wu; Cho-Wei Lin; Kang-Wei Fan; Shue-Fen Luo; Huei-Huang Ho; Lieh-Bang Liou; Wen-Pin Tsai; Ji-Yih Chen; Chung-Han Yang; Chang-Fu Kuo; Kuang-Hui Yu
Journal:  Clin Rheumatol       Date:  2009-02-27       Impact factor: 2.980

Review 5.  Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome.

Authors:  Magdalena Jankowska; Barbara Butto; Alicja Debska-Slizień; Bolesław Rutkowski
Journal:  Rheumatol Int       Date:  2007-01-13       Impact factor: 3.580

Review 6.  Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Authors:  Hidenaga Kawasumi; Takahisa Gono; Yasushi Kawaguchi; Hisashi Yamanaka
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-07-23

Review 7.  Management of Myositis-Associated Interstitial Lung Disease.

Authors:  Tomoyuki Fujisawa
Journal:  Medicina (Kaunas)       Date:  2021-04-03       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.